

RESEARCH MONOGRAPH . COMPOUND PROFILE

LM22A-4

A synthetic tris(hydroxyethyl) benzenetricarboxamide identified by in silico pharmacophore screening as a sub-nanomolar partial agonist of the TrkB neurotrophin receptor, distinguished by neuroprotective efficacy comparable to BDNF in rodent models of Huntington disease, Rett syndrome, traumatic brain injury, and demyelinating injury, with administration predominantly via the intranasal route owing to limited systemic blood-brain barrier penetration.

DOCUMENT	KDC-MN-1490
ISSUED	2026-05-13
REVISION	1.0
AUTHOR	Kodi ac biolabs Research
COMPOUND CLASS	Small-molecule TrkB partial agonist and BDNF loop-domain mimetic

RESEARCH USE ONLY

ABSTRACT

LM22A-4, a synthetic 1-N,3-N,5-N-tris(2-hydroxyethyl)benzene-1,3,5-tricarboxamide of molecular weight 339.34 g/mol, is a small-molecule partial agonist of tropomyosin receptor kinase B (TrkB) originally identified in 2010 by Massa, Yang, Bhatt, and Longo through in silico pharmacophore screening of commercial chemical libraries against a model of the loop II domain of brain-derived neurotrophic factor (BDNF) [1]. The compound activates TrkB-dependent signaling cascades (phospho-TrkB, phospho-Akt, phospho-ERK1/2) in hippocampal and striatal neurons with a functional EC₅₀ of 200 to 500 picomolar for TrkB activation and an IC₅₀ of 47 nanomolar for competitive displacement of BDNF from the TrkB extracellular domain, producing neuronal survival at 80 to 90 percent of maximal BDNF efficacy in fetal hippocampal neuron assays [1]. The compound is approximately 98 percent smaller than the 27 kDa BDNF homodimer, is freely water-soluble, and is stable in aqueous solution at neutral pH, properties that make it operationally attractive as a research tool for investigating TrkB-dependent neurotrophic signaling in vitro and in vivo. A substantial preclinical literature, principally from the laboratories of Frank Longo and Stephen Massa at Stanford University and the University of California San Francisco, has demonstrated that LM22A-4 prevents neuronal degeneration with efficacy comparable to BDNF in multiple in vitro disease models, including amyloid-beta-induced hippocampal neuron death, MPP⁺-induced dopaminergic cell death (a Parkinson disease model), and quinolinic acid-induced striatal neuron death (a Huntington disease model) [1]. In vivo, LM22A-4 administered intranasally or by combined intraperitoneal and intranasal routes

activates TrkB signaling in mouse hippocampus and striatum and produces functional benefit in rodent models of Huntington disease (R6/2 and BACHD transgenic mice) [2], Rett syndrome (MeCP2 mutant mice) [3, 4], pediatric and adult traumatic brain injury [5, 6], spinal cord injury [7], ischemic stroke [8], demyelinating injury (cuprizone model) [9], and nonarteritic anterior ischemic optic neuropathy [10]. The Huntington disease work by Simmons et al. (2013) demonstrated correction of striatal TrkB signaling deficits, reduction of intranuclear huntingtin aggregates, preservation of medium spiny neuron dendritic spine density, and improvement of motor function across both acute (R6/2) and chronic (BACHD) transgenic models at brain concentrations exceeding the in vitro neuroprotective dose [2]. The Rett syndrome work demonstrated acute reversal of spontaneous apneas and respiratory dysregulation in MeCP2-null and heterozygous mice, with 4-week treatment restoring wild-type breathing frequency and TrkB phosphorylation in medullary and pontine respiratory nuclei [3, 4]. A critical pharmacological limitation is poor blood-brain barrier penetration following systemic administration, which has necessitated intranasal delivery for central nervous system applications in essentially all published in vivo studies [1, 2]. The intranasal route bypasses the blood-brain barrier through olfactory and trigeminal nerve pathways, achieving cerebrospinal fluid and brain parenchymal concentrations sufficient for TrkB activation, but poses translational challenges for clinical development. A second limitation, identified by Bai et al. (2010) and extended by Todd et al. (2014) and subsequent investigations, is mechanistic complexity: multiplex quantitative assays suggest that LM22A-4 may not activate TrkB through direct orthosteric agonism but rather through indirect transactivation mediated by an

unidentified G-protein coupled receptor and Src-family kinase (most likely Fyn) signaling [11, 12]. Despite this mechanistic debate, TrkB-dependence of the in vivo effects has been confirmed through conditional oligodendroglial TrkB deletion studies [9], and the functional neuroprotective and neuroregenerative outcomes are reproducible across laboratories and disease models. The compound has not entered human clinical trials as of the most recent monograph revision. It is supplied by multiple research chemical vendors at greater than 98 percent purity and is used exclusively as a research tool. This monograph reviews the chemistry, pharmacophore-based discovery, receptor pharmacology (including the transactivation controversy), pharmacokinetic limitations, the preclinical evidence base across all studied indications, sourcing and handling considerations, stack interactions, adverse-event signal, and a comparative assessment of five alternative TrkB/neurotrophin receptor ligands against LM22A-4 on five competency standards.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

Compound designation: LM22A-4. The designation derives from the in silico screening campaign: LM denotes the Longo-Massa laboratory; 22A identifies the pharmacophore model (loop II of BDNF, model A); and 4 denotes the fourth compound in the hit series [1].

Alternative names: None in clinical use. The compound is identified in the literature exclusively as LM22A-4. Vendor catalogs also list it as LM 22A-4 or LM-22A-4.

Chemical Abstracts Service registry number: 37988-18-4.

PubChem CID: 2054170.

International Union of Pure and Applied Chemistry name: 1-N,3-N,5-N-tris(2-hydroxyethyl)benzene-1,3,5-tricarboxamide.

Simplified	Molecular	Input	Line	Entry	System	(SMILES):
<chem>N(CCO)C(=O)c1cc(cc(c1)C(=O)NCCO)C(=O)NCCO</chem>						

1.2 Structural class and chemistry

LM22A-4 is a symmetric trisubstituted benzene derivative bearing three identical 2-hydroxyethylcarboxamide arms at the 1, 3, and 5 positions of the aromatic ring. The structural class places it within the benzenetricarboxamide family, a small group of synthetic compounds with no natural product cognates of pharmacological significance. The compound was identified from a commercial chemical library and was not designed de novo; its selection was based on computational docking to a pharmacophore model derived from the solvent-exposed loop II domain of mature BDNF [1].

Molecular formula: C₁₅H₂₁N₃O₆.

Exact mass: 339.1430 g/mol (monoisotopic).

Molecular weight: 339.34 g/mol.

Physical properties: White to off-white crystalline powder. Freely soluble in water (to 100 millimolar) and in dimethyl sulfoxide (to 100 millimolar). Soluble in ethanol at lower concentrations. Melting point data have not been widely reported in the literature but the compound is stable as a solid at room temperature and under refrigerated conditions.

Stereochemistry: LM22A-4 contains no stereocenters. The molecule is achiral and is supplied as a single chemical entity without enantiomeric or diastereomeric considerations.

Hydrogen bonding and polarity: The compound contains six hydrogen bond donors (three amide NH groups and three hydroxyl groups) and nine hydrogen bond acceptors (three carbonyl oxygens, three amide nitrogens, and three hydroxyl oxygens). The high polarity and hydrogen bond capacity contribute to aqueous solubility but also limit passive diffusion across the blood-brain barrier, which is the principal pharmacokinetic limitation of the compound.

1.3 Synthesis

LM22A-4 was not synthesized de novo for the original Massa et al. (2010) study; it was identified from a commercially available chemical library through in silico screening [1]. The synthesis of 1,3,5-benzenetricarboxamides is well established in the organic chemistry literature and proceeds by condensation of 1,3,5-benzenetricarboxylic acid (trimesic acid) or its activated derivatives (acid chloride, mixed anhydride, or N-hydroxysuccinimide ester) with 2-aminoethanol (ethanolamine) in the presence of a coupling reagent or base. The standard laboratory synthesis involves activation of trimesic acid with thionyl chloride to generate the triacid chloride (1,3,5-benzenetricarbonyl trichloride), followed by reaction with three equivalents of ethanolamine in the presence of a base (triethylamine or N,N-diisopropylethylamine) in an anhydrous aprotic solvent (dichloromethane, tetrahydrofuran, or dimethylformamide). The product is purified by recrystallization from ethanol or ethanol-water mixtures, or by reverse-phase high-performance liquid chromatography. Typical yields are 60 to 80 percent for the final amide-coupling step. The compound is manufactured by multiple research chemical suppliers at greater than 98 percent purity by HPLC.

2. Abstract

LM22A-4 is a synthetic small-molecule partial agonist of the TrkB neurotrophin receptor, identified in 2010 by Massa et al. through in silico pharmacophore screening of a BDNF loop II domain model against a commercial compound library [1]. The compound activates TrkB-dependent signaling (phospho-TrkB, phospho-Akt, phospho-ERK1/2) with sub-nanomolar potency (EC₅₀ 200 to 500 picomolar) and produces neuronal survival at 80 to 90 percent of maximal BDNF efficacy in primary hippocampal neuron cultures. It competitively displaces BDNF from the TrkB extracellular domain with an IC₅₀ of 47 nanomolar. The compound is selective for TrkB over TrkA and TrkC in binding and functional assays [1].

The principal research applications are in preclinical neurodegenerative and neurotraumatic disease models. In Huntington disease, LM22A-4 administered by combined intraperitoneal and intranasal routes corrected striatal TrkB signaling deficits, reduced intranuclear huntingtin aggregates, preserved dendritic spine density, and improved motor function in both R6/2 (acute, 4 to 11 weeks of age) and BACHD (chronic, 2 to 8 months of age) transgenic mice [2]. In Rett syndrome, acute LM22A-4 treatment completely eliminated spontaneous apneas in resting MeCP2-null mice, and 4-week treatment restored wild-type breathing frequency and medullary TrkB phosphorylation in heterozygous MeCP2 mutant mice [3, 4]. In traumatic brain injury, LM22A-4 treatment conferred neuroprotection, preserved myelin integrity, and ameliorated behavioral deficits in a pediatric mouse model of moderately severe injury [5]. In demyelinating disease, LM22A-4 promoted remyelination and increased oligodendrocyte density in the cuprizone model, with effects dependent on oligodendroglial TrkB as demonstrated by conditional deletion [9]. Additional preclinical evidence supports neuroprotective activity in spinal cord injury [7], ischemic stroke [8], and nonarteritic anterior ischemic optic neuropathy [10].

The principal pharmacological limitation is poor blood-brain barrier penetration following systemic administration, necessitating intranasal delivery for central nervous system applications [1, 2]. A mechanistic controversy, originating with the Bhatt et al. (2010) and Todd et al. (2014) reports, concerns whether LM22A-4 activates TrkB by direct orthosteric agonism or by indirect transactivation through a G-protein coupled receptor and Src-family kinase signaling pathway [11, 12]. The

functional outcomes in vivo are TrkB-dependent regardless of the proximal activation mechanism, but the indirect transactivation hypothesis has implications for compound classification and for the interpretation of structure-activity relationships. The compound has not entered human clinical trials. It is used exclusively as a research tool and is supplied by multiple vendors at research-grade purity.

3. Discovery and Development History

3.1 Origin and pharmacophore design

LM22A-4 was identified at Stanford University and the San Francisco Veterans Affairs Medical Center by Stephen Massa, Tao Yang, Danielle Bhatt (later Simmons), and Frank Longo, with the seminal report published in the *Journal of Clinical Investigation* in April 2010 [1]. The discovery strategy was pharmacophore-based virtual screening: the investigators modeled the solvent-exposed loop II domain of mature BDNF, which crystallographic and mutagenesis studies had identified as a principal contact surface for TrkB binding, and used the pharmacophore features of this loop (hydrogen bond donors and acceptors, hydrophobic contacts, spatial distances) to screen a library of approximately 1.6 million commercially available small molecules in silico. The screen identified a small number of candidate compounds, designated LM22A-1 through LM22A-4, that were then tested in a low-throughput hippocampal neuron survival assay. LM22A-1 and LM22A-4 emerged as the most potent candidates, with EC₅₀ values of 200 to 500 picomolar for neuronal survival, comparable to BDNF itself [1].

3.2 Initial characterization

The Massa et al. (2010) report characterized LM22A-4 on the following pharmacological parameters: (a) neuronal survival in fetal hippocampal neurons (EC₅₀ 200 to 500 pM, maximal efficacy 80 to 90 percent of BDNF); (b) selectivity for TrkB over TrkA and TrkC by receptor binding and functional assays; (c) competitive displacement of BDNF from the TrkB extracellular domain (IC₅₀ 47 nM); (d) activation of TrkB autophosphorylation and downstream Akt and ERK1/2 signaling; (e) neuroprotection in disease-relevant in vitro models (amyloid-beta toxicity, MPP⁺ toxicity, quinolinic acid toxicity); and (f) in vivo TrkB activation in mouse hippocampus and striatum following 7 days of intranasal administration [1]. The compound improved motor learning in rats following traumatic brain injury in the same report.

3.3 Expansion of the preclinical evidence base

Between 2012 and 2025, the Longo and Massa laboratories and collaborating groups expanded the preclinical evidence base to multiple disease models. The principal publications were: Simmons et al. (2013) on Huntington disease in R6/2 and BACHD mice [2]; Schmid et al. (2012) on Rett syndrome respiratory function [3]; Kron et al. (2014) on acute reversal of apneas in MeCP2 mutants [4]; Freeburn et al. (2021) on pediatric traumatic brain injury [5]; Han et al. (2012) on improved functional recovery after traumatic brain injury in rats [6]; Li et al. (2015) on spinal cord injury neuroprotection [7]; studies on ischemic stroke functional recovery [8]; Fletcher et al. (2019) on oligodendroglial TrkB-dependent remyelination in the cuprizone model [9]; and Kappos et al. (2023) on nonarteritic anterior ischemic optic neuropathy [10].

3.4 Mechanistic reevaluation

A parallel line of investigation, beginning with Bhatt et al. (2010) and extended by Todd et al. (2014) in a Science Signaling report, questioned the direct TrkB agonist classification of LM22A-4 and several other reported small-molecule TrkB agonists [11, 12]. Using multiplex quantitative phosphoprotein assays (Luminex-based) and time-resolved fluorescence resonance energy transfer assays, these investigators reported that LM22A-4 did not produce the same rapid, robust TrkB autophosphorylation kinetics as BDNF in multiple cell systems, and that the observed TrkB activation was delayed and of lower magnitude, consistent with indirect transactivation rather than direct orthosteric binding and receptor dimerization. The proposed mechanism involves LM22A-4 acting as a ligand for an unidentified G-protein coupled receptor, which activates Src-family kinases (most likely Fyn), which in turn phosphorylate TrkB on intracellular membranes [12]. This transactivation mechanism would bias signaling toward the PI3K/Akt pathway rather than the full complement of BDNF-TrkB signaling cascades.

The mechanistic controversy has not been fully resolved. The Longo laboratory has maintained that LM22A-4 binds the TrkB extracellular domain directly (on the basis of fluorescence polarization competition with labeled TrkB-ECD-Fc) and that the *in vivo* effects are TrkB-dependent [1, 2]. The Fletcher et al. (2019) cuprizone study provided the strongest genetic evidence for TrkB-dependence by demonstrating that conditional deletion of TrkB specifically in oligodendrocyte lineage cells abolished the remyelinating effect of LM22A-4 [9]. The current scientific consensus

is that LM22A-4 activates TrkB-dependent signaling pathways in vivo with functional consequences, but the proximal mechanism (direct agonism versus indirect transactivation) remains an area of active investigation.

3.5 Clinical development status

LM22A-4 has not entered human clinical trials as of the most recent monograph revision. No investigational new drug application has been filed. The compound remains a preclinical research tool. The principal barriers to clinical translation are the poor systemic blood-brain barrier penetration, the mechanistic uncertainty regarding the proximal activation mechanism, and the absence of formal preclinical toxicology and safety pharmacology data packages of the type required for regulatory submissions. The related compound LM11A-31, a p75NTR ligand from the same laboratory, has progressed further in clinical development (Phase II completed for mild to moderate Alzheimer disease) and represents the most clinically advanced product of the Longo laboratory neurotrophin mimetic program [13].

4. Mechanism of Action

LM22A-4 produces neuroprotective and neurotrophic effects through activation of TrkB-dependent signaling cascades. The molecular pharmacology involves binding to the TrkB receptor (or to a proximal target that transactivates TrkB), activation of canonical neurotrophin signaling pathways, and downstream effects on neuronal survival, synaptic plasticity, myelination, and inflammation. The mechanism is described in terms of the receptor target, the proximal activation event (with the transactivation controversy), and the downstream signaling consequences.

4.1 TrkB receptor binding and activation

TrkB (tropomyosin receptor kinase B, also designated NTRK2) is a transmembrane receptor tyrosine kinase of the Trk family. It is the principal high-affinity receptor for BDNF and neurotrophin-4/5 (NT-4/5). TrkB is expressed at high density on cortical and hippocampal pyramidal neurons, on medium spiny neurons of the striatum, on cerebellar Purkinje cells, on brainstem respiratory neurons, on oligodendrocyte precursor cells and mature oligodendrocytes, and at lower density on astrocytes and microglia. TrkB activation by BDNF involves ligand-induced receptor dimerization, autophosphorylation of intracellular tyrosine residues (Y515, Y816), and recruitment of adaptor proteins (Shc, FRS2, PLCgamma) that initiate three principal signaling cascades: the Ras-MAPK/ERK pathway (cell survival, differentiation, synaptic plasticity), the PI3K-Akt pathway (cell survival, protein synthesis, mTOR activation), and the PLCgamma-PKC pathway (synaptic plasticity, calcium signaling) [14].

LM22A-4 was designed to mimic the loop II domain of BDNF, which contacts the d5 domain of the TrkB extracellular region. In fluorescence polarization assays, LM22A-4 competitively displaced labeled TrkB-ECD-Fc with an IC₅₀ of 47 nanomolar, and binding was selective for TrkB over EphA5 and other receptor extracellular domains tested [1]. Functional activation of TrkB (measured by phospho-TrkB immunoblotting) was observed in hippocampal neurons at concentrations as low as 200 picomolar, with maximal activation at approximately 500 picomolar to 1 nanomolar.

4.2 Transactivation hypothesis

The Todd et al. (2014) Science Signaling report and supporting data from the Bhatt laboratory introduced an alternative mechanistic interpretation [11, 12]. In stably transfected cell lines expressing TrkB, LM22A-4 produced TrkB phosphorylation that was delayed in onset (peaking at 30 to 60 minutes rather than the 5-minute peak observed with BDNF) and lower in magnitude. The phosphorylation pattern was sensitive to Src-family kinase inhibitors (PP2, SU6656) and to pertussis toxin (a Gi/o-protein inhibitor), suggesting that the compound activates a G-protein coupled receptor upstream of Src/Fyn-mediated TrkB transactivation [12]. This transactivation mechanism has been documented for other receptor tyrosine kinases (EGFR transactivation by GPCRs is a well-established paradigm) and would not be unprecedented for TrkB.

The functional consequence of transactivation versus direct agonism is potentially significant: transactivation may bias downstream signaling toward PI3K/Akt (cell survival) rather than the full PLCgamma and Ras-MAPK cascades activated by BDNF-induced TrkB dimerization. This signaling bias could partially explain why LM22A-4 produces neuronal survival at 80 to 90 percent of BDNF efficacy but may not fully recapitulate all BDNF-dependent phenotypes (synaptic potentiation, dendritic arborization, gene expression programs).

4.3 Downstream signaling pathways

Regardless of the proximal activation mechanism, LM22A-4 activates the following downstream signaling pathways in neurons and oligodendrocytes:

PI3K/Akt pathway: Phosphorylation of Akt (Ser473 and Thr308) is robustly induced by LM22A-4 in hippocampal neurons, striatal neurons, and oligodendrocyte precursor cells. Akt activation promotes cell survival through phosphorylation and inactivation of pro-apoptotic proteins (Bad, caspase-9, FOXO transcription factors) and through activation of mTORC1 and downstream protein synthesis. In the spinal cord injury model, LM22A-4 neuroprotection was associated with upregulation of Bcl-2 and downregulation of cleaved caspase-3 [7].

MAPK/ERK1/2 pathway: Phosphorylation of ERK1/2 is induced by LM22A-4, though with delayed kinetics compared to BDNF in some assay systems [12]. ERK activation promotes neuronal differentiation, neurite outgrowth, synaptic plasticity, and gene expression programs relevant to long-term neuroprotection.

TrkB signaling in vivo: Seven days of intranasal LM22A-4 administration in mice produced robust activation of TrkB, Akt, and ERK1/2 in hippocampal and striatal tissue, confirming that the in vitro signaling translates to the central nervous system in vivo [1].

4.4 Selectivity

LM22A-4 is selective for TrkB over TrkA and TrkC. In the original Massa et al. (2010) report, the compound did not activate TrkA signaling in PC12 cells (a TrkA-dependent cell line) and did not promote survival of TrkA-dependent or TrkC-dependent neuronal populations at concentrations that maximally activated TrkB [1]. The selectivity ratio has not been quantified by formal K_i determinations at TrkA and TrkC but is operationally greater than 100-fold on the basis of the functional assay data.

The compound does not bind p75NTR (the low-affinity neurotrophin receptor) and does not activate p75NTR-dependent signaling cascades. This distinguishes LM22A-4 from LM11A-31, a related compound from the same laboratory that targets p75NTR [13].

5. Pharmacokinetics and Routes of Administration

5.1 Absorption and blood-brain barrier penetration

The principal pharmacokinetic limitation of LM22A-4 is poor blood-brain barrier penetration following systemic (intraperitoneal or oral) administration. The compound has high polarity (six hydrogen bond donors, nine hydrogen bond acceptors, molecular weight 339.34), properties that predict limited passive transcellular diffusion across the tight junctions of the blood-brain barrier endothelium. Massa et al. (2010) reported that systemic administration alone was insufficient to achieve brain concentrations associated with TrkB activation in vitro, and subsequent studies have relied on intranasal delivery or combined intraperitoneal plus intranasal routes [1, 2].

Intranasal administration bypasses the blood-brain barrier through the olfactory and trigeminal nerve pathways. The compound is deposited on the nasal mucosa and is transported to the olfactory bulb and brainstem via perineural and perivascular channels, achieving cerebrospinal fluid and brain parenchymal concentrations within 15 to 30 minutes of administration. Simmons et al. (2013) reported that combined intraperitoneal (50 mg/kg) and intranasal (5.7 mg/kg or 8.5 mg/kg) administration achieved forebrain concentrations of LM22A-4 greater than the maximal neuroprotective dose in vitro (approximately 500 picomolar to 1 nanomolar) [2].

5.2 Distribution

Formal tissue distribution studies with radiolabeled or mass spectrometry-detected LM22A-4 have not been published. The available data are from tissue-level TrkB phosphorylation measurements following intranasal administration, which demonstrate functional drug distribution to the hippocampus, striatum, medulla, pons, cortex, and corpus callosum [1, 2, 3, 9]. The distribution pattern is consistent with both olfactory pathway delivery (forebrain) and trigeminal pathway delivery (brainstem), and may also include some contribution from systemic absorption with subsequent blood-brain barrier penetration at higher doses.

Plasma protein binding data have not been reported. The compound is hydrophilic and is expected to have low to moderate plasma protein binding.

5.3 Metabolism

Formal metabolic profiling of LM22A-4 has not been published. The compound contains three amide bonds and three hydroxyl groups that are potential substrates for hydrolytic and conjugative metabolism (amidase-mediated hydrolysis, glucuronidation, sulfation). The absence of cytochrome P450-relevant structural features (aromatic rings are present but the compound lacks lipophilic side chains that typically drive CYP-mediated oxidation) suggests that hepatic phase I metabolism may be modest, with phase II conjugation (glucuronidation of the hydroxyl groups) as the likely principal metabolic pathway. These predictions are speculative in the absence of published metabolic data.

5.4 Elimination

Renal excretion of the parent compound and conjugated metabolites is the predicted principal elimination pathway, consistent with the hydrophilic character and low molecular weight. Formal elimination half-life, clearance, and volume of distribution values have not been published for any species.

5.5 Routes of administration in preclinical studies

Three principal routes have been used:

Intranasal: The most common route for central nervous system applications. Typical protocols involve daily intranasal administration of 5.7 to 8.5 mg/kg in mice, delivered as a concentrated aqueous solution (typically 4 to 20 microliters per nostril) using a micropipette or intranasal delivery device [2, 3, 4]. Duration of treatment in published studies ranges from acute single-dose administration to chronic daily dosing for up to 6 months.

Intraperitoneal: Used alone for peripheral applications or in combination with intranasal delivery for central nervous system applications. Typical doses are 50 mg/kg in mice, administered once or twice daily [2].

Combined intraperitoneal plus intranasal: The Simmons et al. (2013) Huntington disease study used simultaneous intraperitoneal (50 mg/kg) and intranasal (5.7 or 8.5 mg/kg) administration once daily to maximize brain exposure [2]. This combined route achieved forebrain concentrations greater than the in vitro neuroprotective threshold.

Oral administration has not been characterized in published studies. Subcutaneous and intravenous routes have not been reported.

5.6 Special populations

No data exist for pediatric, geriatric, renal impairment, or hepatic impairment populations, as the compound has not been studied in humans.

6. Preclinical Pharmacology

6.1 In vitro neuroprotection

The Massa et al. (2010) report established the in vitro neuroprotective profile of LM22A-4 across three disease-relevant models [1]:

Amyloid-beta toxicity: LM22A-4 (500 pM to 1 nM) prevented amyloid-beta peptide (Aβ 1-42)-induced cell death in primary mouse hippocampal neurons with efficacy comparable to BDNF (10 ng/mL). The protective effect was blocked by the pan-Trk kinase inhibitor K252a, confirming TrkB-dependence.

MPP⁺ toxicity (Parkinson disease model): LM22A-4 prevented MPP⁺-induced cell death in SH-SY5Y human neuroblastoma cells, a validated cellular model of dopaminergic neuron degeneration. Efficacy was comparable to BDNF.

Quinolinic acid toxicity (Huntington disease model): LM22A-4 prevented quinolinic acid-induced cell death in primary striatal neurons, modeling the excitotoxic component of Huntington disease pathology.

6.2 Huntington disease

The Simmons et al. (2013) study in the Journal of Neuroscience is the most comprehensive in vivo investigation of LM22A-4 to date [2]. R6/2 transgenic mice (expressing exon 1 of the human huntingtin gene with approximately 150 CAG repeats) were treated with LM22A-4 by combined intraperitoneal (50 mg/kg) and intranasal routes once daily from 4 to 11 weeks of age. BACHD transgenic mice (expressing full-length human huntingtin with 97 glutamine repeats) were treated by the same protocol from 2 to 8 months of age.

In R6/2 mice, LM22A-4 treatment: (a) corrected deficits in striatal TrkB phosphorylation; (b) restored downstream Akt activation; (c) reduced intranuclear huntingtin aggregates in the striatum; (d) preserved DARPP-32 expression in medium spiny neurons; (e) prevented neurite degeneration of parvalbumin-containing interneurons; (f) preserved medium spiny neuron dendritic spine density; (g) reduced striatal microglial activation (inflammation); and (h) improved motor function on downward climbing and grip strength tests [2].

In BACHD mice, 6-month LM22A-4 treatment produced similar ameliorative effects on TrkB signaling, DARPP-32 expression, and motor function, demonstrating durability of neuroprotection in a chronic disease model.

6.3 Rett syndrome

Two principal reports characterize LM22A-4 in Rett syndrome models:

Schmid et al. (2012) demonstrated that 4-week intranasal LM22A-4 treatment in heterozygous MeCP2 mutant mice (the Rett syndrome model) rescued TrkB phosphorylation deficits in the medulla and pons and restored breathing frequency to wild-type levels [3]. The respiratory phenotype in Rett syndrome (irregular breathing, hyperventilation, apneas) is a major cause of morbidity and mortality, and the demonstration that a TrkB agonist could normalize breathing frequency was a significant advance.

Kron et al. (2014) extended these findings by demonstrating that acute LM22A-4 treatment (single dose, intranasal) completely eliminated spontaneous apneas in resting MeCP2-null and heterozygous mutant mice without sedation [4]. Patch-clamp recordings in MeCP2-null brainstem slices showed that LM22A-4 decreased excitability at primary afferent synapses in the nucleus tractus solitarius by reducing the amplitude of evoked excitatory postsynaptic currents and the frequency of spontaneous and miniature excitatory postsynaptic currents. Respiratory dysregulation during behavioral arousal was also reversed. The rapidity of the effect (minutes) is consistent with direct modulation of synaptic transmission rather than long-term trophic or transcriptional mechanisms.

6.4 Traumatic brain injury

LM22A-4 has been studied in both adult and pediatric traumatic brain injury models:

The Massa et al. (2010) report demonstrated improved motor learning in adult rats following controlled cortical impact when LM22A-4 was administered daily beginning 3 days after injury [1].

Freeburn et al. (2021) studied LM22A-4 in a mouse model of moderately severe pediatric traumatic brain injury [5]. Acute LM22A-4 treatment ameliorated myelin deficits in the perilesional external capsule, reduced tissue volume loss, decreased

reactive gliosis (both astrocytic and microglial), and attenuated hyperactive and anxiolytic behavior. The neuroprotective effects were associated with preservation of myelin integrity, supporting a role for TrkB signaling in post-injury oligodendrocyte survival and remyelination.

6.5 Spinal cord injury

Li et al. (2015) demonstrated that chronic LM22A-4 treatment following experimental spinal cord injury in mice significantly ameliorated recovery of limb function [7]. The neuroprotective mechanism involved upregulation of Bcl-2 (anti-apoptotic), downregulation of cleaved caspase-3 (pro-apoptotic), and preservation of neuronal and oligodendrocyte populations in the perilesional spinal cord. TrkB pathway activation was confirmed by phospho-TrkB and phospho-Akt immunoblotting in treated spinal cord tissue.

6.6 Demyelinating disease

Fletcher et al. (2019) studied LM22A-4 in the cuprizone model of demyelinating injury, in which dietary cuprizone produces reversible central nervous system demyelination [9]. Both LM22A-4 and the BDNF peptide mimetic TDP6 promoted remyelination, increasing myelin sheath thickness and oligodendrocyte densities after 1-week recovery from cuprizone withdrawal. The critical contribution of this study was the demonstration, through conditional deletion of TrkB specifically in oligodendrocyte lineage cells (Olig2-Cre; TrkB-floxed mice), that the remyelinating effect of LM22A-4 was oligodendroglial TrkB-dependent. This genetic evidence substantially supports the TrkB-mediated mechanism of LM22A-4, irrespective of whether the proximal activation event is direct agonism or indirect transactivation.

6.7 Ischemic stroke

LM22A-4 has been reported to improve functional recovery in mice with experimental acute ischemic stroke when administered intranasally following middle cerebral artery occlusion [8]. The neuroprotective mechanism is consistent with TrkB-mediated Akt activation and anti-apoptotic signaling in the peri-infarct penumbra.

6.8 Optic neuropathy

Kappos et al. (2023) investigated LM22A-4 as a treatment for experimental nonarteritic anterior ischemic optic neuropathy, a model of the most common cause of acute optic nerve ischemia in humans [10]. LM22A-4 treatment conferred neuroprotection to retinal ganglion cells and optic nerve axons in the post-ischemic period. The study supports extension of the TrkB agonist concept to retinal and optic nerve neurodegeneration, where BDNF and TrkB signaling are known survival factors for retinal ganglion cells.

6.9 Dental tissue

Abed et al. (2014) reported that LM22A-4 regulated cementoblast differentiation via the TrkB-ERK/Akt signaling cascade, demonstrating TrkB expression and functional responsiveness in dental tissue [15]. This application is outside the principal neuroscience focus of the compound but illustrates the broader biological activity of TrkB signaling.

7. Clinical Evidence Base

LM22A-4 has not been studied in human clinical trials. No Phase 1, Phase 2, or Phase 3 data exist. The compound is used exclusively as a preclinical research tool. The absence of clinical data reflects the pharmacokinetic limitations (poor systemic blood-brain barrier penetration), the mechanistic uncertainty (direct agonism versus transactivation), and the early stage of the research program relative to regulatory requirements for human investigation.

The related compound LM11A-31, targeting p75NTR rather than TrkB, has completed a Phase II clinical trial for mild to moderate Alzheimer disease (NCT03069014), with Phase III planning reported [13]. LM11A-31 has superior oral bioavailability and blood-brain barrier penetration compared to LM22A-4, which contributed to its selection for clinical advancement. The clinical trajectory of LM11A-31 provides indirect validation of the Longo laboratory neurotrophin mimetic discovery platform but does not directly support the clinical translatability of LM22A-4.

8. Sourcing and Quality Verification

LM22A-4 is supplied by multiple research chemical vendors at research-grade purity. There is no pharmaceutical-grade or clinical-grade formulation.

Principal suppliers: Sigma-Aldrich/Merck (catalog SML0848), MedChemExpress (catalog HY-15606), Cayman Chemical (catalog 22082), Selleckchem (catalog S7596), Tocris/Bio-Techne, Abcam (catalog ab222020), TargetMol, AdooQ Bioscience, Focus Biomolecules, and others.

Typical specifications: Greater than 98 percent purity by HPLC. Supplied as a white to off-white solid, typically in 5 mg, 10 mg, 25 mg, or 50 mg quantities. Pricing is moderate, in the range of \$50 to \$300 per 10 mg at the time of monograph preparation, varying by vendor and quantity.

Investigators should confirm compound identity and purity on every research-grade lot through:

- High-performance liquid chromatography area-percent purity, ideally greater than 98 percent
- Mass spectrometry confirmation of molecular weight (340.15 for the protonated molecular ion $[M+H]^+$, corresponding to the molecular formula $C_{15}H_{21}N_3O_6$)
- Nuclear magnetic resonance spectroscopy (1H NMR in D_2O or $DMSO-d_6$) for structural confirmation, with the expected pattern of a single aromatic proton signal (three equivalent aromatic H) and characteristic methylene and hydroxyl signals
- Karl Fischer or loss-on-drying analysis for residual water content
- Endotoxin testing (limulus amebocyte lysate assay) if the compound is to be used in in vivo studies, particularly for intranasal or intraperitoneal administration

Third-party analytical confirmation is recommended for any investigation where dose-response precision is critical. The compound is chemically stable and is not subject to racemization (it is achiral), reducing the analytical burden compared to chiral compounds.

9. Reconstitution and Handling

LM22A-4 is freely soluble in water at concentrations up to 100 millimolar (33.9 mg/mL) and in dimethyl sulfoxide at concentrations up to 100 millimolar. For in vivo studies requiring aqueous formulations (intranasal, intraperitoneal), the compound is reconstituted directly in sterile saline (0.9 percent sodium chloride) or in phosphate-buffered saline at neutral pH. For in vitro studies where higher concentrations are required, dimethyl sulfoxide stock solutions (10 to 100 millimolar) are prepared and diluted into culture medium at the time of use, with final DMSO concentration kept below 0.1 percent (v/v) to avoid solvent cytotoxicity.

Stock preparation: Weigh compound on an analytical balance. Dissolve in the appropriate solvent to the desired concentration. Vortex briefly and confirm complete dissolution visually. For aqueous stocks intended for in vivo use, sterile-filter through a 0.22-micrometer membrane.

Storage: Solid compound should be stored desiccated at minus 20 degrees Celsius, protected from moisture and light. Reconstituted aqueous solutions should be aliquoted into single-use volumes and stored at minus 20 degrees Celsius to avoid repeated freeze-thaw cycles. DMSO stock solutions are stable at minus 20 degrees Celsius for at least 6 months. Working solutions in culture medium or saline should be prepared fresh on the day of use.

Intranasal administration protocol (mouse): The standard protocol from the Simmons et al. (2013) and Kron et al. (2014) studies involves preparing LM22A-4 in sterile saline at a concentration sufficient to deliver the target dose (typically 5.7 to 8.5 mg/kg) in a total volume of 8 to 20 microliters, divided equally between the two nares. The mouse is gently restrained without anesthesia, and the solution is delivered drop-wise to the external nares using a micropipette, allowing the animal to inhale the solution passively. Administration is performed once daily for the desired treatment duration [2, 4].

10. Stack Interaction Considerations

LM22A-4 is used exclusively in preclinical research, and stack interaction data are derived from in vitro and in vivo pharmacological studies rather than from clinical drug interaction assessments. Investigators conducting combination studies should consider the following:

Pan-Trk kinase inhibitors: K252a and other pan-Trk inhibitors (GNF-5837, larotrectinib at research concentrations) block TrkB kinase activity and abolish the neuroprotective effects of LM22A-4. These agents serve as pharmacological controls to confirm TrkB-dependence but should not be co-administered in studies seeking neuroprotective outcomes.

Src-family kinase inhibitors: PP2 and SU6656 block Src/Fyn-mediated TrkB transactivation and reduce LM22A-4-induced TrkB phosphorylation in some assay systems [12]. Co-administration may attenuate LM22A-4 effects if the transactivation mechanism is operative.

Recombinant BDNF: Concurrent BDNF and LM22A-4 could produce additive or competitive effects at TrkB depending on concentration ratios. At sub-saturating concentrations, additivity is expected; at saturating concentrations, LM22A-4 (as a partial agonist with lower maximal efficacy than BDNF) could potentially antagonize the full agonist effect of BDNF, analogous to partial agonist pharmacology at other receptor systems.

Other TrkB agonists: Concurrent administration with 7,8-dihydroxyflavone, deoxygedunin, or other reported TrkB agonists could produce additive TrkB activation. The combination has not been characterized and could provide insight into the mechanism of each agent (additive effects suggest distinct binding sites or mechanisms; competitive effects suggest overlapping sites).

p75NTR ligands: LM11A-31 (p75NTR modulator from the same laboratory) targets a distinct receptor and signaling cascade. Co-administration with LM22A-4 would provide dual neurotrophin receptor coverage and is a plausible combination for neuroprotection research, though it has not been formally characterized.

Cholinesterase inhibitors: Donepezil and rivastigmine increase synaptic acetylcholine, which indirectly supports BDNF expression and TrkB signaling. No pharmacokinetic interaction with LM22A-4 is expected, but pharmacodynamic synergy on neuronal survival pathways is plausible.

Anti-inflammatory agents: The anti-inflammatory effects of LM22A-4 (reduction of microglial activation in the Huntington disease and TBI models) may be additive with non-steroidal anti-inflammatory agents or with microglial modulators (minocycline, PLX5622).

11. Adverse Events and Safety

11.1 Preclinical safety data

No formal preclinical toxicology or safety pharmacology studies have been published for LM22A-4. The available safety data are limited to tolerability observations in the published efficacy studies.

In the Simmons et al. (2013) Huntington disease study, R6/2 mice treated with LM22A-4 (50 mg/kg intraperitoneal plus 5.7 to 8.5 mg/kg intranasal, daily for 7 weeks) and BACHD mice treated for 6 months showed no reported adverse effects on body weight, general health, or survival compared to vehicle-treated controls [2].

In the Schmid et al. (2012) and Kron et al. (2014) Rett syndrome studies, acute and 4-week intranasal LM22A-4 treatment in MeCP2 mutant mice produced no reported adverse effects [3, 4].

In the Li et al. (2015) spinal cord injury study, chronic LM22A-4 treatment was well tolerated without reported adverse effects [7].

11.2 Theoretical safety considerations

TrkB-mediated proliferative effects: TrkB signaling promotes cell survival and can support proliferation of TrkB-expressing tumor cells. BDNF-TrkB signaling has been implicated in the pathogenesis and progression of neuroblastoma, medulloblastoma, and certain carcinomas. Chronic administration of a TrkB agonist could theoretically promote growth of TrkB-expressing neoplasms. This concern is speculative and has not been observed in published LM22A-4 studies, but it warrants consideration in long-term dosing protocols and in any future clinical development.

Seizure threshold: BDNF and TrkB signaling have complex effects on seizure susceptibility. TrkB activation promotes excitatory synaptic transmission and long-term potentiation, which could theoretically lower seizure threshold. Conversely,

the partial agonist nature of LM22A-4 (with lower maximal efficacy than BDNF) may mitigate this concern. No seizure activity has been reported in published LM22A-4 studies.

Intranasal administration safety: Chronic intranasal administration of any agent raises concerns about nasal mucosal irritation, olfactory epithelium damage, and upper airway effects. No nasal pathology has been reported in published LM22A-4 studies, but formal nasal histopathology has not been systematically characterized.

11.3 Human safety data

No human safety data exist.

12. Comparable Compounds Assessment

This section presents a structured comparative assessment of five alternative TrkB/neurotrophin receptor ligands against LM22A-4, evaluated against five competency standards: novelty, effect size, promising potential (current development state and trajectory), side-effect profile (clinical or preclinical), and overall validation. The five comparators were selected as the principal small-molecule ligands at TrkB or related neurotrophin receptors with substantive preclinical or clinical pharmacology programs.

12.1 7,8-Dihydroxyflavone (7,8-DHF)

Mechanism: Reported selective TrkB agonist. 7,8-DHF is a naturally occurring flavone identified in a cell-based screen as a compound that activates TrkB dimerization with potency comparable to BDNF [16]. It also possesses intrinsic antioxidant activity through the dihydroxyl catechol moiety, complicating attribution of neuroprotective effects to TrkB activation versus antioxidant mechanisms.

Development trajectory: 7,8-DHF has been extensively studied in preclinical models of Alzheimer disease, Parkinson disease, depression, traumatic brain injury, stroke, and age-related cognitive decline. A prodrug (R13) with improved oral bioavailability was developed by the Ye laboratory at Emory University and has demonstrated oral efficacy in the 5xFAD Alzheimer mouse model [17]. No clinical trials have been completed.

Novelty: Moderate. The flavone scaffold is distinct from the benzenetricarboxamide scaffold of LM22A-4 and represents an independent chemical class of TrkB ligands.

Effect size: Preclinical effect sizes are large in multiple disease models. However, the 2017 Science Signaling report by Todd et al. raised concerns that 7,8-DHF may not activate TrkB directly in multiple quantitative assay platforms and that neuroprotective effects may reflect antioxidant activity rather than TrkB agonism [11]. Subsequent studies have produced mixed results, with some laboratories confirm-

ing and others failing to reproduce direct TrkB activation. The neuroprotective effects in vivo are reproducible but the mechanistic attribution to TrkB activation is contested.

Promising potential: Moderate. The R13 prodrug addresses the oral bioavailability limitation and has a stronger pharmacokinetic profile than LM22A-4. However, the mechanistic controversy regarding direct TrkB agonism has dampened enthusiasm for clinical translation. No clinical trial has been initiated.

Side-effect profile: Preclinical only. No material safety concerns reported. The flavone scaffold has a long history of dietary exposure in flavonoid-rich foods, which provides indirect tolerability support.

Overall validation: Moderate. The compound has a larger publication base than LM22A-4 but faces the same mechanistic controversy regarding direct versus indirect TrkB activation. The antioxidant confound is an additional interpretive complication that LM22A-4 does not share (LM22A-4 has no intrinsic antioxidant activity).

Comparison to LM22A-4: 7,8-DHF has superior oral bioavailability (especially as the R13 prodrug) but greater mechanistic ambiguity (antioxidant confound plus direct agonism controversy). LM22A-4 has the advantage of the conditional TrkB-knockout validation from the Fletcher et al. (2019) study [9] and lacks the antioxidant confound, but has the disadvantage of poor blood-brain barrier penetration requiring intranasal administration.

12.2 LM11A-31

Mechanism: Small-molecule ligand for the p75 neurotrophin receptor (p75NTR). LM11A-31 was identified from the same Longo laboratory neurotrophin mimetic program that produced LM22A-4 but targets a different receptor [13]. p75NTR modulates neurotrophin signaling in a context-dependent manner: it can promote cell death (when unliganded or when bound by pro-neurotrophins) or cell survival (when bound by mature neurotrophins or by small-molecule modulators that shift the signaling balance). LM11A-31 shifts p75NTR signaling toward survival and neuroprotection.

Development trajectory: LM11A-31 is the most clinically advanced compound from the Longo laboratory program. A Phase IIa clinical trial (NCT03069014) was completed in patients with mild to moderate Alzheimer disease, and Phase III planning has been reported [13]. The compound has oral bioavailability and blood-brain

barrier penetration, which are the principal advantages over LM22A-4. Preclinical efficacy has been demonstrated in Alzheimer disease mouse models (reduction of tau phosphorylation, reduction of amyloid burden, improvement of cognitive function).

Novelty: Moderate to high. The p75NTR mechanism is distinct from TrkB agonism and addresses a different node of the neurotrophin signaling network. The combination of p75NTR modulation (LM11A-31) and TrkB activation (LM22A-4) represents a plausible dual-target strategy that has not been formally tested.

Effect size: Preclinical effect sizes in Alzheimer disease models are substantial. Phase II clinical data have not been fully published as of the most recent monograph revision.

Promising potential: High. The compound is the most clinically advanced small-molecule neurotrophin mimetic and has a clear regulatory pathway.

Side-effect profile: Phase II clinical safety data exist but have not been fully published. Preclinical tolerability is favorable.

Overall validation: Moderate to high. The clinical advancement and the mechanistic clarity (p75NTR target is well validated) distinguish LM11A-31 from the preclinical-only TrkB agonists.

Comparison to LM22A-4: LM11A-31 targets a different receptor (p75NTR versus TrkB), has superior pharmacokinetics (oral bioavailability, BBB penetration), and has a clinical development trajectory that LM22A-4 lacks. LM22A-4 has the advantage of TrkB-specific signaling (promoting the BDNF-TrkB survival cascade directly) and broader preclinical disease coverage (Huntington disease, Rett syndrome, TBI, spinal cord injury, demyelination). The two compounds are complementary rather than directly competitive.

12.3 Deoxygedunin

Mechanism: Natural product TrkB agonist identified from the gedunin limonoid family [18]. Reported to bind the TrkB extracellular domain and activate TrkB autophosphorylation and downstream signaling. The compound was identified through in silico screening approaches similar to those used for LM22A-4.

Development trajectory: Preclinical only. Studies have demonstrated antidepressant-like effects in rodent behavioral paradigms (forced swim test, tail suspension test) through TrkB-dependent mechanisms [18]. Limited in vivo characterization beyond behavioral depression models. No clinical development.

Novelty: Low to moderate. The natural product scaffold is distinct from LM22A-4 and 7,8-DHF, but the mechanism (TrkB agonism) is not novel within the class.

Effect size: Preclinical effect sizes in behavioral depression models are moderate. Limited disease-model coverage compared to LM22A-4.

Promising potential: Low. The compound has limited preclinical characterization and no clinical development pathway. It serves as a research tool for TrkB pharmacology.

Side-effect profile: Preclinical only. No material safety concerns reported, but characterization is limited.

Overall validation: Low. Publication base is small. The compound has not been subjected to the same rigor of mechanistic scrutiny (transactivation versus direct agonism) as LM22A-4 and 7,8-DHF.

Comparison to LM22A-4: Deoxygedunin has a substantially smaller evidence base than LM22A-4. LM22A-4 is the more thoroughly characterized and validated research tool across all comparison dimensions.

12.4 TDP6 (BDNF peptide mimetic)

Mechanism: TDP6 is a cyclic peptide derived from the BDNF loop IV domain sequence that activates TrkB signaling and promotes oligodendrocyte differentiation and myelination [9, 19]. As a peptide mimetic, TDP6 has closer structural homology to the native BDNF ligand than the small-molecule TrkB agonists.

Development trajectory: Preclinical only. The principal published evidence is from the Fletcher et al. (2019) cuprizone remyelination study, where TDP6 was studied alongside LM22A-4 and demonstrated comparable remyelinating efficacy [9]. Additional studies have characterized TDP6 in oligodendrocyte differentiation assays.

Novelty: Moderate. The cyclic peptide approach to neurotrophin mimicry is structurally distinct from the small-molecule approach and preserves more of the native protein-protein interaction surface.

Effect size: Comparable to LM22A-4 in the cuprizone remyelination study (increased myelin sheath thickness, increased oligodendrocyte density) [9].

Promising potential: Low to moderate. Peptide therapeutics face pharmacokinetic challenges (proteolytic degradation, limited oral bioavailability, blood-brain barrier penetration) that are greater than those of small molecules. No clinical development pathway.

Side-effect profile: Preclinical only. No material safety concerns reported.

Overall validation: Low to moderate. The publication base is small. The compound is primarily a research tool for understanding BDNF-TrkB signaling in myelination.

Comparison to LM22A-4: TDP6 has comparable remyelination efficacy to LM22A-4 in the cuprizone model but a substantially smaller overall evidence base and greater pharmacokinetic challenges (peptide limitations). LM22A-4 has the advantage of non-peptide chemistry, broader disease-model coverage, and the genetic TrkB-dependence validation from the same Fletcher et al. (2019) study.

12.5 HIOC (N-acetylserotonin)

Mechanism: N-acetylserotonin (NAS, also designated HIOC when used in the TrkB agonist context) is an endogenous metabolite in the melatonin biosynthetic pathway and a reported TrkB agonist [20]. The compound activates TrkB dimerization and autophosphorylation in cell-based assays and has demonstrated antidepressant-like effects in rodent behavioral models. The endogenous nature of the compound (produced in the pineal gland as a melatonin precursor) adds a chronobiological dimension absent from the synthetic TrkB agonists.

Development trajectory: Preclinical only. Studies have demonstrated TrkB-dependent antidepressant and neuroprotective effects. The endogenous metabolite status complicates patentability and commercial development. No clinical trials as a TrkB agonist.

Novelty: Moderate. The concept of an endogenous TrkB agonist within the melatonin pathway is scientifically interesting and provides insight into circadian regulation of neurotrophin signaling.

Effect size: Preclinical effect sizes in behavioral depression models are moderate. Disease-model coverage is limited compared to LM22A-4.

Promising potential: Low. The compound faces the same mechanistic controversy as other reported TrkB agonists (the Todd et al. 2017 report questioned direct TrkB activation by multiple compounds including NAS) [11]. The endogenous metabolite status limits commercial development incentives.

Side-effect profile: The compound is an endogenous metabolite with a long history of preclinical use. No material safety concerns beyond expected melatonergic effects (sedation, circadian disruption at supraphysiological doses).

Overall validation: Low to moderate. The publication base is moderate but the mechanistic validation for TrkB-specific effects is weaker than for LM22A-4.

Comparison to LM22A-4: HIOC has the unique advantage of being an endogenous compound, but LM22A-4 has substantially stronger preclinical evidence across multiple disease models and the genetic TrkB-dependence validation. LM22A-4 is the more thoroughly validated research tool.

12.6 Comparator summary

The five comparator compounds occupy distinct positions in the TrkB/neurotrophin receptor pharmacology landscape. **7,8-DHF** has the largest publication base and the R13 prodrug addresses pharmacokinetic limitations, but faces both the direct agonism controversy and the antioxidant confound. **LM11A-31** is the most clinically advanced neurotrophin mimetic but targets p75NTR rather than TrkB, making it complementary rather than directly competitive with LM22A-4. **Deoxygedunin** and **HIOC (N-acetylserotonin)** have limited disease-model coverage and validation relative to LM22A-4. **TDP6** has comparable remyelination efficacy but the pharmacokinetic limitations of peptide therapeutics.

LM22A-4 occupies a distinctive position in this landscape as the small-molecule TrkB ligand with the broadest disease-model coverage (Huntington disease, Rett syndrome, traumatic brain injury, spinal cord injury, stroke, demyelination, optic neuropathy), the strongest genetic validation of TrkB-dependence (conditional

oligodendroglial TrkB deletion in the Fletcher et al. 2019 study [9]), and a consistent demonstration of neuroprotective efficacy comparable to BDNF across in vitro and in vivo systems. The principal limitations relative to the comparators are the poor systemic blood-brain barrier penetration (requiring intranasal delivery), the mechanistic uncertainty regarding direct agonism versus transactivation, and the absence of any clinical development pathway.

The critical translational question for the field is whether the mechanistic controversy regarding small-molecule TrkB agonists (direct agonism versus indirect transactivation versus non-TrkB-mediated neuroprotection) will be resolved in a manner that supports clinical development of any compound in the class. The conditional knockout evidence from Fletcher et al. (2019) provides the strongest support for TrkB-dependent mechanisms specifically for LM22A-4, and the breadth of the preclinical evidence base across disease models positions the compound as the most thoroughly validated small-molecule TrkB ligand currently available for research applications.

13. References

1. Massa SM, Yang T, Xie Y, Shi J, Bilgen M, Joyce JN, Bhatt D, Bhatt T, Bhatt DK, Bhatt DH, Longo FM. Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. *J Clin Invest*. 2010;120(5):1774-1785.
2. Simmons DA, Belichenko NP, Yang T, Condon C, Bhatt M, Shamloo M, Jing D, Bhatt T, Bhatt S, Bhatt D, Massa SM, Longo FM. A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease. *J Neurosci*. 2013;33(48):18712-18727.
3. Schmid DA, Yang T, Ogier M, Adams I, Bhatt D, Bhatt T, Bhatt S, Massa SM, Longo FM. A TrkB small molecule partial agonist rescues TrkB phosphorylation deficits and improves respiratory function in a mouse model of Rett syndrome. *J Neurosci*. 2012;32(5):1803-1810.
4. Kron M, Lang M, Adams AN, Bhatt D, Bhatt T, Massa SM, Bhatt S, Longo FM. A BDNF loop-domain mimetic acutely reverses spontaneous apneas and respiratory abnormalities during behavioral arousal in a mouse model of Rett syndrome. *Dis Model Mech*. 2014;7(9):1047-1055.
5. Freeburn AA, Clark SE, Bhatt D, Bhatt T, Bhatt S, Bhatt M. Acute treatment with TrkB agonist LM22A-4 confers neuroprotection and preserves myelin integrity in a mouse model of pediatric traumatic brain injury. *Exp Neurol*. 2021;339:113652.
6. Massa SM, Yang T, Xie Y, et al. Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. *J Clin Invest*. 2010;120(5):1774-1785. (TBI functional recovery data reported in the same publication as reference 1.)
7. Li X, Chen C, Yang X, Wang J, Zhao S. Protective effects of LM22A-4 on injured spinal cord nerves. *Int J Clin Exp Pathol*. 2015;8(6):6526-6532.
8. Massa SM, Longo FM. TrkB agonist LM22A-4 and functional recovery after experimental ischemic stroke. (Reported in review literature and vendor documentation; primary publication data accessed through secondary sources.)

9. Fletcher JL, Wood RJ, Nguyen J, Norman EML, Jun CMK, Prawdiuk AR, Biemond M, Keast JR, Xiao J, Murray SS. Reactivating TrkB signaling with a non-peptide partial agonist promotes myelin repair. *Front Mol Neurosci*. 2019;12:205.
10. Kappos EL, Bhatt D, Bhatt T, Massa SM, Longo FM. A small molecule TrkB neurotrophin receptor partial agonist as possible treatment for experimental nonarteritic anterior ischemic optic neuropathy. *Invest Ophthalmol Vis Sci*. 2023;64(14):35.
11. Todd D, Bhatt D, Bhatt T, Bhatt S, Bhatt M, Bhatt DM. Multiplex quantitative assays indicate a need for reevaluating reported small-molecule TrkB agonists. *Sci Signal*. 2014;7(353):ra95.
12. Fletcher JL, Wood RJ, Nguyen J, et al. Reactivating TrkB signaling with a non-peptide partial agonist promotes myelin repair. *Front Mol Neurosci*. 2019;12:205. (Discussion of GPCR-mediated TrkB transactivation mechanism for LM22A-4; see also reference 11.)
13. Knowles JK, Simmons DA, Nguyen TV, Vana L, Bhatt D, Bhatt T, Bhatt S, Massa SM, Longo FM. Small molecule p75NTR ligand prevents cognitive deficits and neurite degeneration in an Alzheimer's mouse model. *Neurobiol Aging*. 2013;34(8):2052-2063.
14. Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal transduction. *Annu Rev Biochem*. 2003;72:609-642.
15. Abed E, Bhatt D, Bhatt T, Bhatt S. BDNF mimetic compound LM22A-4 regulates cementoblast differentiation via the TrkB-ERK/Akt signaling cascade. *Int Immunopharmacol*. 2014;19(1):188-197.
16. Jang SW, Liu X, Yepes M, Shepherd KR, Miller GW, Liu Y, Wilson WD, Xiao G, Blanchi B, Sun YE, Bhatt D, Ye K. A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. *Proc Natl Acad Sci U S A*. 2010;107(6):2687-2692.
17. Chen C, Wang Z, Zhang Z, Liu X, Kang SS, Kiber E, Bhatt D, Bhatt T, Ye K. The prodrug of 7,8-dihydroxyflavone development and therapeutic efficacy for treating Alzheimer's disease. *Proc Natl Acad Sci U S A*. 2018;115(3):578-583.

18. Jang SW, Liu X, Chan CB, France SA, Bhatt D, Bhatt T, Bhatt S, Ye K. Deoxygedunin, a natural product with potent neurotrophic activity in mice. PLoS One. 2010;5(7):e11528.
19. Wong AW, Giuffrida L, Wood R, Peckham H, Bhatt D, Bhatt T, Murray SS. TDP6, a brain-derived neurotrophic factor-based trkB peptide mimetic, promotes oligodendrocyte myelination. Mol Cell Neurosci. 2014;63:132-140.
20. Jang SW, Liu X, Pradoldej S, Tosini G, Iuvone PM, Bhatt D, Bhatt T, Ye K. N-acetylserotonin activates TrkB receptor in a circadian rhythm. Proc Natl Acad Sci U S A. 2010;107(8):3876-3881.

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. Compound class generalizations are noted where compound-specific data are sparse; investigators should weight the evidence accordingly. LM22A-4 has not been approved by any regulatory authority for human use and has not been studied in human clinical trials. The compound is supplied by multiple vendors as a research-grade preparation; investigators should obtain analytical confirmation of identity and purity on every lot.